WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318999

CAS#: 68291-97-4

Description: Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure.

Chemical Structure

CAS# 68291-97-4

Theoretical Analysis

MedKoo Cat#: 318999
Name: Zonisamide
CAS#: 68291-97-4
Chemical Formula: C8H8N2O3S
Exact Mass: 212.03
Molecular Weight: 212.223
Elemental Analysis: C, 45.28; H, 3.80; N, 13.20; O, 22.62; S, 15.11

Price and Availability

Size Price Availability Quantity
100mg USD 250
200mg USD 450
500mg USD 650
1g USD 950
2g USD 1550
5g USD 3450 2 Weeks
Bulk inquiry

Synonym: AD-810; AD 810; AD810; CI-912; CI 912; CI912; Zonisamide; Exceglan; Excegram; PD 110843; PD-110843; PD110843;

IUPAC/Chemical Name: benzo[d]isoxazol-3-ylmethanesulfonamide


InChi Code: InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 212.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Janszky J, Horvath R, Komoly S. [ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY]. Ideggyogy Sz. 2015 May 30;68(5-6):149-53. Review. Hungarian. PubMed PMID: 26182605.

2: Romigi A, Femia EA, Fattore C, Vitrani G, Di Gennaro G, Franco V. Zonisamide in the management of epilepsy in the elderly. Clin Interv Aging. 2015 Jun 8;10:931-7. doi: 10.2147/CIA.S50819. eCollection 2015. Review. PubMed PMID: 26089654; PubMed Central PMCID: PMC4467644.

3: Jion YI, Raff A, Grosberg BM, Evans RW. The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension. Headache. 2015 Jan;55(1):161-6. doi: 10.1111/head.12480. Epub 2014 Dec 9. Review. PubMed PMID: 25486999.

4: Afra P, Adamolekun B. Update on once-daily zonisamide monotherapy in partial seizures. Neuropsychiatr Dis Treat. 2014 Mar 19;10:493-8. doi: 10.2147/NDT.S39152. eCollection 2014. Review. PubMed PMID: 24672240; PubMed Central PMCID: PMC3964158.

5: Hoy SM. Zonisamide: a review of its use as adjunctive therapy in the management of partial seizures in pediatric patients aged ≥6 years. Paediatr Drugs. 2014 Jun;16(3):235-46. doi: 10.1007/s40272-014-0072-6. Review. PubMed PMID: 24668240.

6: Cox JH, Seri S, Cavanna AE. Zonisamide as a treatment for partial epileptic seizures: a systematic review. Adv Ther. 2014 Mar;31(3):276-88. doi: 10.1007/s12325-014-0104-1. Epub 2014 Feb 13. Review. PubMed PMID: 24522856.

7: Carmichael K, Pulman J, Lakhan SE, Parikh P, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013 Dec 19;12:CD001416. doi: 10.1002/14651858.CD001416.pub3. Review. PubMed PMID: 24353187.

8: Grover ND, Limaye RP, Gokhale DV, Patil TR. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Indian J Pharmacol. 2013 Nov-Dec;45(6):547-55. doi: 10.4103/0253-7613.121266. Review. PubMed PMID: 24347760; PubMed Central PMCID: PMC3847242.

9: Hoy SM. Zonisamide: a review of its use in the management of adults with partial seizures. Drugs. 2013 Aug;73(12):1321-38. doi: 10.1007/s40265-013-0093-4. Review. PubMed PMID: 23873520.

10: Verrotti A, Loiacono G, Di Sabatino F, Zaccara G. The adverse event profile of zonisamide: a meta-analysis. Acta Neurol Scand. 2013 Nov;128(5):297-304. doi: 10.1111/ane.12147. Epub 2013 Jun 13. Review. PubMed PMID: 23763367.

11: Mula M. Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults. Drug Des Devel Ther. 2013 May 14;7:397-402. doi: 10.2147/DDDT.S43612. Print 2013. Review. PubMed PMID: 23700365; PubMed Central PMCID: PMC3660130.

12: Villanueva V, Serrano-Castro PJ. [Zonisamide in the epilepsy treatment: a literature review from add-on therapy to monotherapy]. Rev Neurol. 2013 Apr 16;56(8):429-38. Review. Spanish. PubMed PMID: 23568686.

13: Sierra-Hidalgo F, de Pablo-Fernández E. Palinopsia induced by topiramate and zonisamide in a patient with migraine. Clin Neuropharmacol. 2013 Mar-Apr;36(2):63-4. doi: 10.1097/WNF.0b013e3182849208. Review. PubMed PMID: 23503550.

14: Dupont S, Stefan H. Zonisamide in clinical practice. Acta Neurol Scand Suppl. 2012;(194):29-35. doi: 10.1111/ane.12017. Review. PubMed PMID: 23106523.

15: Brodie MJ, Ben-Menachem E, Chouette I, Giorgi L. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand Suppl. 2012;(194):19-28. doi: 10.1111/ane.12016. Review. PubMed PMID: 23106522.

16: Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol. 2012;(209):433-66. doi: 10.1007/978-3-642-24716-3_20. Review. PubMed PMID: 22249827.

17: Holder JL Jr, Wilfong AA. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2011 Nov;12(16):2573-81. doi: 10.1517/14656566.2011.622268. Epub 2011 Oct 4. Review. PubMed PMID: 21967409.

18: Murata M. [Discovery of an antiparkinsonian drug: zonisamide]. Rinsho Shinkeigaku. 2010 Nov;50(11):780-2. Review. Japanese. PubMed PMID: 21921440.

19: Zaccara G, Tramacere L, Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy. Expert Opin Drug Saf. 2011 Jul;10(4):623-31. doi: 10.1517/14740338.2011.571201. Epub 2011 Mar 29. Review. PubMed PMID: 21663459.

20: Verdier MC, Bentué-Ferrer D, Tribut O; le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. [Therapeutic drug monitoring of zonisamide]. Therapie. 2010 Jan-Feb;65(1):29-34. doi: 10.2515/therapie/2009062. Epub 2010 Mar 8. Review. French. PubMed PMID: 20205992.